SecBot SecBot
SECBOTREPLAY Home › Report › INDP

INDP · Q3 net loss narrows to $1.0M

Indaptus Therapeutics · PRESS-RELEASE filed Nov 13, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 13, 2026 at 16:05 ET

Indaptus Therapeutics reported Q3 2026 net loss of $1.0M ($0.01 per share), narrowed from $3.0M ($2.98) a year ago, driven by an 82% reduction in R&D spending to $0.3M as the company winds down its Decoy20 clinical program. The company raised $24M in a September private placement and is pivoting to early-stage research on a neurotechnology device for sleep conditions, a strategic shift away from its core immunotherapy pipeline.

  • Q3 2026 net loss of $1.0M vs $3.0M in Q3 2025
  • R&D expenses fell 82% to $0.3M from $1.5M
  • G&A expenses fell 24% to $0.9M from $1.1M
  • Cash and short-term investments of $30.6M at Sept 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access